Fund Holdings — CAXTON CORP

Total Portfolio Value
$24.16M
Total Bought
$1.04M
Total Sold
$210.2K
Net Transaction
+$834.1K
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
XERIS BIOPHARMA HOLDINGS INC5,113,3485,113,348011,50514,57360.31%+3,068
REZOLUTE INC(RZLT)1,318,9671,318,96705,6726,39726.47%+725
SPDR S&P 500 ETF TR(SPY)1,8692,867+9981,0171,6456.81%+628
BICARA THERAPEUTICS INC010,941+10,94102791.15%+279
BERKSHIRE HATHAWAY INC DEL1,0251,151+1264175302.19%+113
COMPASS THERAPEUTICS INC(CMPX)43,46543,465043800.33%+37
ADICET BIO INC17,48817,488021250.10%+4
CONTEXT THERAPEUTICS INC(CNTX)18,40318,403037360.15%-1
MIND MEDICINE MINDMED INC30,38334,073+3,6902191940.80%-25
ABIVAX SA(ABVX)13,90011,365-2,5351841310.54%-53
KYVERNA THERAPEUTICS INC(KYTX)22,98122,98101721120.47%-60
LEXEO THERAPEUTICS INC(LXEO)17,85117,85102861610.67%-125
MOLECULAR TEMPLATES INC136,8660-136,8661570—-157
Page 1 of 1
CAXTON CORP — 13F Holdings — Q3 2024 | TickerTrail